What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “CD34 + autologous hematopoietic stem and progenitor cells edited at the BCL11A enhancer site”In the company’s words, NCT05577312 on ClinicalTrials.gov
- Tested for
- Beta-Thalassemia
- Main trialPhase 1/2
- “This is a non-randomized, open label, multi-site, single-dose, phase 1/2 study in subjects with Transfusion-Dependent β-Thalassemia (TDT). The study will evaluate the safety and efficacy of autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells (hHSPCs) (BRL-101)”In the company’s words, NCT05577312 on ClinicalTrials.gov
Other drugs for Beta-Thalassemia
- CTX001Vertex Pharmaceuticals · Phase 3
- REGN7999Regeneron · Phase 2
- Vebeglogene autotemcelLantu Biopharma · Phase 1/2
- 9MW3011Mabwell · Phase 1
- LuspaterceptCelgene · Marketed (Phase 4 trial)
Coming up0
No dates coming up.
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1/2Active, not recruiting | 20 Oct 2026 | Safety and Efficacy Evaluation of BRL-101 in Subjects With Transfusion-Dependent β-Thalassemia |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026